This episode, 'Plasmids: Tackling Supply Chain and Manufacturing Challenges,' explores the critical supply chain and manufacturing hurdles impacting the life science industry, especially in gene therapy. We'll uncover effective strategies for securing plasmids of the necessary grades, vital for advancing life-changing treatments.
Join us as we speak with Matthew Hewitt, Vice President and Technical Officer for CGT & Biologics at Charles River Laboratories.
Matthew will explore:
- Strategies for providing plasmids across all necessary grades, ensuring quality and consistency.
- How process standardization can significantly simplify complex supply chains.
- The crucial role of maintaining larger material stocks to overcome long-lead time consumable issues.
- How these integrated approaches collectively streamline operations and accelerate gene therapy advancements.
- His expert insights on the future trajectory of gene therapy.
All content for Drug Target Review Podcast is the property of Drug Target Review and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This episode, 'Plasmids: Tackling Supply Chain and Manufacturing Challenges,' explores the critical supply chain and manufacturing hurdles impacting the life science industry, especially in gene therapy. We'll uncover effective strategies for securing plasmids of the necessary grades, vital for advancing life-changing treatments.
Join us as we speak with Matthew Hewitt, Vice President and Technical Officer for CGT & Biologics at Charles River Laboratories.
Matthew will explore:
- Strategies for providing plasmids across all necessary grades, ensuring quality and consistency.
- How process standardization can significantly simplify complex supply chains.
- The crucial role of maintaining larger material stocks to overcome long-lead time consumable issues.
- How these integrated approaches collectively streamline operations and accelerate gene therapy advancements.
- His expert insights on the future trajectory of gene therapy.
Navigating the neurological frontier - 2024 and beyond
Drug Target Review Podcast
23 minutes 51 seconds
1 year ago
Navigating the neurological frontier - 2024 and beyond
As we step into the new year, we explore research insights and projections for the field in 2024 in neuroscience.
In this episode titled: Navigating the neurological frontier - 2024 and beyond, we want to find out what are the most exciting recent advancements in neuroscience, setting the stage for the future.
This conversation features Dr Alessio Travaglia, Director, Translational Science at the Foundation for National Institutes of Health (FNIH), and Dr Steve Hoffman, Associate Vice President, Science Partnerships, Translational Science, and Director of the Biomarkers Consortium at the Foundation for the National Institutes of Health (FNIH).
Drug Target Review Podcast
This episode, 'Plasmids: Tackling Supply Chain and Manufacturing Challenges,' explores the critical supply chain and manufacturing hurdles impacting the life science industry, especially in gene therapy. We'll uncover effective strategies for securing plasmids of the necessary grades, vital for advancing life-changing treatments.
Join us as we speak with Matthew Hewitt, Vice President and Technical Officer for CGT & Biologics at Charles River Laboratories.
Matthew will explore:
- Strategies for providing plasmids across all necessary grades, ensuring quality and consistency.
- How process standardization can significantly simplify complex supply chains.
- The crucial role of maintaining larger material stocks to overcome long-lead time consumable issues.
- How these integrated approaches collectively streamline operations and accelerate gene therapy advancements.
- His expert insights on the future trajectory of gene therapy.
